Targeted Therapy & Precision Oncology
Part of Healthcare - Oncology
| Ticker | Company | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | $0.8t | $905.90 | -1.8% | 4.2M |
 RVMD | Revolution Medicines, Inc. Common Stock | $18.4b | $152.58 | +3.8% | 11.9M |
 INCY | Incyte Genomics Inc | $18.0b | $97.06 | -0.6% | 1.2M |
 JAZZ | Jazz Pharmaceuticals, Inc. | $11.3b | $199.23 | -0.9% | 658.4K |
 EXEL | Exelixis Inc | $10.9b | $44.28 | -3.5% | 2.2M |
 NUVL | Nuvalent, Inc. Class A Common Stock | $7.6b | $104.70 | -0.3% | 619.1K |
 HALO | Halozyme Therapeutics, Inc. | $7.4b | $68.04 | +1.1% | 1.2M |
 COGT | Cogent Biosciences, Inc. Common Stock | $5.7b | $36.30 | -0.5% | 1.5M |
 CELC | Celcuity Inc. Common Stock | $5.2b | $123.35 | +2.1% | 701.5K |
 ERAS | Erasca, Inc. Common Stock | $4.6b | $18.20 | +2.0% | 6.5M |
 CORT | Corcept Therapeutics Inc. | $4.1b | $43.94 | +0.6% | 840.7K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | $2.8b | $32.16 | -0.6% | 2.2M |
 TNGX | Tango Therapeutics, Inc. | $2.7b | $25.32 | +5.2% | 4.4M |
 ELVN | Enliven Therapeutics, Inc. Common Stock | $2.7b | $43.92 | -2.1% | 865.8K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | $2.2b | $21.48 | +0.1% | 1.0M |
 IMNM | Immunome, Inc. | $2.2b | $23.38 | +2.1% | 648.9K |
 TYRA | Tyra Biosciences, Inc. Common Stock | $1.9b | $34.95 | -0.9% | 1.1M |
 ZYME | Zymeworks Inc. | $1.8b | $27.75 | +2.9% | 789.9K |
 RLAY | Relay Therapeutics, Inc. Common Stock | $1.7b | $15.48 | +5.0% | 3.9M |
 NRIX | Nurix Therapeutics, Inc. Common stock | $1.5b | $16.98 | +4.1% | 1.7M |
 DMRA | Damora Therapeutics, Inc. Common Stock | $1.5b | $26.73 | +0.0% | 293.2K |
 NUVB | Nuvation Bio Inc. | $1.4b | $4.83 | -0.3% | 1.8M |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | $1.4b | $10.28 | -2.4% | 1.8M |
 VIR | Vir Biotechnology, Inc. Common Stock | $1.4b | $10.45 | +4.0% | 2.2M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | $1.2b | $18.23 | +4.2% | 944.2K |
 BHVN | Biohaven Ltd. | $1.2b | $10.40 | -0.4% | 2.0M |
 NVCR | NovoCure Limited Ordinary Shares | $1.2b | $12.17 | +7.7% | 2.0M |
 OLMA | Olema Pharmaceuticals, Inc. Common Stock | $1.2b | $16.47 | +1.0% | 677.4K |
 AVBP | ArriVent BioPharma, Inc. Common Stock | $0.9b | $29.40 | +6.4% | 594.3K |
 GERN | Geron Corp | $0.9b | $1.70 | -4.2% | 21.0M |
 URGN | UroGen Pharma Ltd. Ordinary Shares | $0.8b | $21.53 | +1.5% | 816.5K |
 BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | $0.7b | $9.39 | +2.3% | 535.6K |
 KURA | Kura Oncology, Inc. | $0.7b | $9.07 | -0.8% | 874.2K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.7b | $7.17 | -0.3% | 1.3M |
 ARVN | Arvinas, Inc | $0.7b | $10.97 | -0.2% | 607.1K |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $475.1m | $32.02 | +2.0% | 382.2K |
 ADCT | ADC Therapeutics SA | $462.4m | $4.38 | +13.5% | 2.7M |
 VSTM | Verastem, Inc. | $426.0m | $6.33 | +3.1% | 2.0M |
 STRO | Sutro Biopharma, Inc. | $399.3m | $29.86 | +3.8% | 315.6K |
 MNPR | Monopar Therapeutics Inc. Common Stock | $356.6m | $57.75 | -0.3% | 145.3K |
 IMRX | Immuneering Corporation Class A Common Stock | $315.5m | $5.75 | +6.3% | 894.2K |
 PBYI | PUMA BIOTECHNOLOGY INC | $311.9m | $7.47 | -1.3% | 262.8K |
 DCTH | Delcath Systems Inc | $308.9m | $10.99 | +1.0% | 283.9K |
 CCCC | C4 Therapeutics, Inc. | $229.3m | $2.90 | +5.1% | 1.9M |
 TLSI | TriSalus Life Sciences, Inc. Common Stock | $227.4m | $4.50 | +2.3% | 163.2K |
 NVCT | Nuvectis Pharma, Inc. Common Stock | $198.4m | $8.50 | -2.6% | 49.7K |
 PRLD | Prelude Therapeutics Incorporated | $193.4m | $5.47 | +24.3% | 974.8K |
 NTHI | NeOnc Technologies Holdings, Inc. Common Stock | $171.6m | $5.11 | -5.2% | 31.8K |
 WHWK | Whitehawk Therapeutics, Inc. Common Stock | $154.8m | $3.90 | -2.4% | 316.5K |
 CRBP | Corbus Pharmaceuticals Holdings, Inc. | $152.5m | $10.03 | +0.1% | 225.9K |